U.S. Markets open in 8 hrs 21 mins

Some Accelerate Diagnostics (NASDAQ:AXDX) Shareholders Are Down 19%

Simply Wall St

It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do both better or worse than that. For example, the Accelerate Diagnostics, Inc. (NASDAQ:AXDX) share price is down 19% in the last year. That's disappointing when you consider the market returned 3.3%. Even if shareholders bought some time ago, they wouldn't be particularly happy: the stock is down 17% in three years. Unfortunately the last month hasn't been any better, with the share price down 26%.

Check out our latest analysis for Accelerate Diagnostics

Accelerate Diagnostics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Accelerate Diagnostics grew its revenue by 49% over the last year. That's well above most other pre-profit companies. Given the revenue growth, the share price drop of 19% seems quite harsh. Our sympathies to shareholders who are now underwater. Prima facie, revenue growth like that should be a good thing, so it's worth checking whether losses have stabilized. Our brains have evolved to think in linear fashion, so there's value in learning to recognize exponential growth. We are, in some ways, simply the wisest of the monkeys.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

NasdaqCM:AXDX Income Statement, August 5th 2019

We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. So it makes a lot of sense to check out what analysts think Accelerate Diagnostics will earn in the future (free profit forecasts).

A Different Perspective

Investors in Accelerate Diagnostics had a tough year, with a total loss of 19%, against a market gain of about 3.3%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 0.5% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. Investors who like to make money usually check up on insider purchases, such as the price paid, and total amount bought. You can find out about the insider purchases of Accelerate Diagnostics by clicking this link.

Accelerate Diagnostics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.